About this episode

Dr Andree Bates interviews Bret Bostwick about his journey from genetics to venture capital and its implications for healthcare innovation.

In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Bret Bostwick from Breyer Capital about the rare path from genetics, clinical medicine and drug development into venture capital, and what that perspective reveals about the future of healthcare innovation. Bret shares how the release of the Human Genome Project first pulled him into genetics, and how clinical work with patients made the science deeply practical. As a medical geneticist, he saw families finally receive a diagnosis, but often without a treatment option. That experience led him towards programmable therapeutics, RNA-based medicines and the translational work required to move from biological insight into human trials. The conversation explores what makes a therapeutic company investable beyond the science alone. Bret explains why breakthroughs often fail not just because of technical risk, but because the right people, culture, operating experience and business model are not around the table. For him, one of the first questions is not simply “does the science work?” but “what problem is this company really solving, and is this the most elegant solution?” They also discuss where AI is overhyped and…

People in this episode

Host: Dr Andree Bates

Guest: Bret Bostwick

Topics covered

• genetics
• venture capital
• healthcare innovation
• programmable therapeutics
• RNA-based medicines
• AI in medicine

Keywords

• genetics
• venture capital
• healthcare
• AI
• therapeutics
• Human Genome Project
• clinical medicine

Mentioned in this episode

Organizations: Breyer Capital, Human Genome Project

More episodes of AI For Pharma Growth

• E234: The contrarian case for physics over data: can deterministic, training-free models beat ML in lead optimization? · September 8, 2026 · 44 min
• E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named · September 1, 2026 · 43 min
• E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner · August 25, 2026 · 28 min
• E231: The Diagnostic Room: You didn't have an AI problem. You had a capability problem. · August 18, 2026 · 37 min
• E230: The Last Untouched Dataset · August 11, 2026 · 24 min
• E229: From Reactive to Proactive: What a QP's Job Should Actually Look Like in 2026 · August 4, 2026 · 33 min

Explore listener stats, chart rankings, contacts and more on the AI For Pharma Growth podcast page.